1Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the european society of cardiology[J]. Eur Heart J,2005,26(8) : 804 -847.
4Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month cllnical outcome of thrombotic stent occlusion after bare-metal, simlimus, or paclitaxel stent implantation [J]. J Am Col Cardiol,2005,45(6)..947-953.
6Atwater BD,Roe MT, Mahaffey KW, et al. Platelet glycoprotein Ⅱb/Ⅲ a receptor antagonists in non ST segment elevation acutecoronary syndromes: a review and guide to patient selection[J]. Drugs,2005,65(3) : 313-324.
7Kim JH,Jeong MH,Rhew JY,et al. Longterm clinical outcomes of platelet glycoprotein Ⅱ b/Ⅲ a in hibitor combined with low molecular weight heparin in patients with acute coronary syndrome[J]. Cire J, 2005,69 (2) : 159-164.
9Chen Y, Davis GG, Watson RR, et al. Platetet CD62 pexpression and microparticle in murine acquired immune deficieney syndrome and ethanol eonsumption[J]. Alcohol, 2003,38(1) : 25-30.
7Steinhubl SR,Talley JD,Braden GA,et al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD (AU-Assessing Ultegra) multicenter study.Circulation.2001;103(21):2572-2578.
8Rao AK,Pratt C,Berke A,et al.Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.J Am Coll Cardiol.1988;11(1):1-11.
9van der Zee PM,Biró E,Ko Y,et al.P-selectin-and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction.Clin Chem.2006;52(4):657-664.
10Libby P,Ridker PM,Maseri A.Inflammation and atherosclerosis.Circulation.2002;105(9):1135-1143.
